Fedratinib (SAR302503; TG101348) is a JAK2-selective inhibitor that was developed as a treatment for MPNs based on pre-clinical data that showed it caused a reduction in JAK2 mutant allele burden and BMF in murine models of myeloproliferative disease [22, 23]. Here, JAK2 is linked to myeloproliferative disorder.